COVID-19

ACTIVITIES

88710562_l.jpg
24 February 2021

Amarex Featured in 15-year Anniversary Issue of the NSF International Journal

The just released Issue 48 of NSF International’s Health Science Journal features contributions by Amarex. The journal is available at https://www.nsf.org/periodicals/health-sciences-journal/issue-48.

Business woman consultant and businessma
15 February 2021

Amarex Job Openings at the BioCapital Life Sciences Career Fair | Feb. 18, 2021

We are featuring current job openings at the MD Tech Council BioCapital Life Sciences Career Fair, Thursday, February 18th. This virtual event is free and open to all students and job seekers interested in career opportunities in the life sciences industry. Register for this virtual event, visit our booth, and speak to an Amarex representative about expanding your career: mdls.vfairs.com.

113804482_l.jpg
25 January 2021

Enrichment Strategies to Increase the Power/Reduce the Sample Size in Clinical Trials

On January 07, Dr. Kazem Kazempour, President & CEO, conducted the webinar Enrichment Strategies to Increase the Power/Reduce the Sample Size in Clinical Trials. View the full webinar recording on our YouTube channel.

90176245_l.jpg
18 January 2021

Severe-to-Critical COVID-19 Patient Clinical Trial Reaches Full Enrollment

Our client’s Phase III clinical trial for patients with severe-to-critical COVID-19 symptoms reached full enrollment (390 patients) in mid-December. Data analysis results are expected this quarter. The trial was conducted in the U.S., Canada, and U.K.. 

As a full-service, international CRO, Amarex Clinical Research has extensive experience successfully performing clinical studies across all phases of research and discovery, development, validation and approval.​​​

Recommended by the people who matter most: our clients.

VP, Clinical Development

A Canadian Device Company

 

Chief Medical Officer 

A Maryland Biotech Company

To this focused and hard-working team: I count myself lucky to work with such caring individuals.Thanks for being some of the most interesting and high performing people I've ever worked with.

We have worked with Amarex on numerous projects and they consistently deliver high quality reliable service by leveraging a broad array of clinical and regulatory expertise. What sets them apart from other CROs is a creative entrepreneurial approach to drug development. They go beyond the technical aspects of clinical trial development and work with the sponsor to drive value and increase chances for success.

        

             5/5

        

             5/5

Chief Technical Officer

A Canadian-based Infectious Diseases Organization

[Thank you to the team at Amarex] for the statistical support which proved to be invaluable and completely accurate in the final review by FDA. The cornerstone of this milestone achievement was the data from the clinical study, including the limit of detection study, and we came through [all FDA reviews with solid outcomes throughout]. From all of us here, a sincere thank you and well done to all at Amarex who worked on this project. We look forward to working with you again as we apply the successful platform to other diagnostic device developments in the future.

        

             5/5

AMAREX_NSF_1C.png
  • Facebook Social Icon
  • Twitter Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon

           

           © 2021 Amarex Clinical Research, LLC, an NSF International company. All rights reserved.                                                                                                                                                                                                  Top of Page 

Contact     Subscribe     Privacy Policy     Clinical Site Registration     WebView

NSF Mark_100x100.jpg